Chang-Qi Zhu

Erlotinib in lung cancer - molecular and clinical predictors of outcome.

Lesley Seymour, Ming-Sound Tsao, Suzanne Kamel-Reid, 2005, The New England journal of medicine.

Prognostic gene-expression signature of carcinoma-associated fibroblasts in non-small cell lung cancer

Nikolina Radulovich, Igor Jurisica, Melania Pintilie, 2011, Proceedings of the National Academy of Sciences.

Integrated Omic analysis of lung cancer reveals metabolism proteome signatures with prognostic impact

Paul Taylor, Michael F Moran, Yuhong Wei, 2014, Nature Communications.

Validation of a Histology-Independent Prognostic Gene Signature for Early-Stage, Non–Small-Cell Lung Cancer Including Stage IA Patients

Igor Jurisica, Melania Pintilie, Ming-Sound Tsao, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer.

Igor Jurisica, Matthew Meyerson, Lesley Seymour, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Integrative Genomic Analyses Identify BRF2 as a Novel Lineage-Specific Oncogene in Lung Squamous Cell Carcinoma

Calum MacAulay, John D. Minna, John Yee, 2010, PLoS medicine.

Three-gene prognostic classifier for early-stage non small-cell lung cancer.

Igor Jurisica, Shaf Keshavjee, Paul C Boutros, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21.

Lesley Seymour, Ming-Sound Tsao, Suzanne Kamel-Reid, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.